Nonalcoholic Steatohepatitis (NASH) is a progressive liver disease characterized by inflammation, hepatocellular damage, and fibrosis. As a severe form of Non-Alcoholic Fatty Liver Disease (NAFLD), its rising prevalence underscores the urgent need for effective treatments. Currently, there are no FDA-approved therapies for NASH, making it a focal point for drug development. With...